[Daratumumab for the treatment of relapsed T-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a case report]

Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):698. doi: 10.3760/cma.j.cn121090-20231130-00285.

[Article in Chinese]

Authors

X Wang¹, M M Hu¹, J Y Xiao², Z H Lin¹, T T Shi¹, X F Li¹, H Y Qiu²

Affiliations

¹ Hygeia Suzhou Yongding Hospital, Suzhou 215200, China.
² Department of Hematology, First Affiliated Hospital of Suzhou University, Suzhou 215006, China.

PMID: 39231777
PMCID: PMC11388128
DOI: 10.3760/cma.j.cn121090-20231130-00285

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal* / administration & dosage
Antibodies, Monoclonal* / therapeutic use
Hematopoietic Stem Cell Transplantation* / methods
Humans
Male
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy
Transplantation, Homologous

Substances

Antibodies, Monoclonal
daratumumab